Advent Life Sciences: Investment Portfolio & Startup News
Advent Life Sciences
To add a bio or update investment portfolio click update information.
Investment Portfolio


T-Therapeutics
5 Nov 2026
T-Therapeutics closes a £100m Series B led by Advent Life Sciences and British Business Bank to take its cancer and autoimmune treatments into clinical trials
T-Therapeutics is a biotechnology company developing T cell engager treatments based on human T cell receptors. Its drug programmes target cancer and autoimmune diseases.


Cyted Health
1 Sept 2025
Cyted Health raises £32.5m Series B led by British Business Bank, EQT and Advent Life Sciences to expand gastrointestinal diagnostics
Cyted Health develops minimally invasive diagnostic tests for gastrointestinal disease, combining cell collection devices with molecular biomarkers to detect conditions earlier.
Advent Life Sciences
- 1(12 months)
- adventls.com
More venture news
- 17 Nov 2026

Model MLModel ML secures a £190m Series B led by General Atlantic and QED Investors to expand its AI operating system for financial services
Series BFintech - 16 Nov 2026

SubdialSubdial secures a £15m Series B led by Gresham House Ventures to buy and sell pre-owned watches
Series BConsumer - 12 Nov 2026

GriffinGriffin closes a £15m Series B led by Octagon Partners to add cards and stablecoin payments to its banking platform
Series BFintech